Financhill is a comprehensive financial analysis platform that provides stock analysis, market data, investment tools, and educational resources to help investors make informed decisions.

How do I get started with Financhill?

You can start by creating a free account, exploring our stock analysis tools, setting up a watchlist, or trying our 7-day trial for full access to all premium features.

What features does Financhill offer?

Financhill offers stock analysis, technical charts, fundamental data, earnings information, dividend tracking, portfolio management, market screening tools, and educational resources.

What information is available on company profile pages?

Company profile pages provide comprehensive information including financial statements, earnings data, analyst ratings, institutional ownership, insider trading, SEC filings, and detailed business analysis.

How do I analyze a company's financial health?

Use our financial metrics including P/E ratio, debt-to-equity, revenue growth, profit margins, and cash flow analysis to evaluate a company's financial strength and growth potential.

How do I analyze VINC stock?

Use our comprehensive analysis tools including technical charts, fundamental metrics, earnings data, and Stock Score to evaluate VINC investment potential.

What is VINC stock price today?

The current VINC stock price is $0.01 as of 23 Dec '25. Get real-time VINC stock price, historical data, and price charts on Financhill.

Is VINC a good investment?

Evaluate VINC investment potential using our Stock Score, fundamental analysis, technical indicators, and earnings data. Consider your risk tolerance and investment goals.

What does Vincerx Pharma, Inc. (VINC) do?

Vincerx Pharma, Inc. (VINC) is a publicly traded company. View detailed company information, business model, financial statements, and corporate data on our VINC company profile page.

How to buy VINC stock?

To buy VINC stock, open a brokerage account, research the company using our analysis tools, and place your order through your broker. Always do your own research before investing.

What is the market cap of VINC?

View detailed market capitalization data and company valuation metrics for VINC on our comprehensive analysis page.

What is the P/E ratio of VINC?

Use our fundamental analysis tools to view VINC P/E ratio and compare valuation metrics with industry peers.

What are VINC earnings?

View VINC earnings data, quarterly results, revenue growth, and profit margins on our comprehensive earnings analysis page. Track earnings trends and analyst estimates.

Sell

14

VINC Quote, Financials, Valuation and Earnings

Last price:

$0.0100

Seasonality move :

18.63%

Day range:

$0.0125 - $0.0125

52-week range:

$0.0002 - $10.3740

Dividend yield:

0%

P/E ratio:

--

P/S ratio:

--

P/B ratio:

0.03x

Volume:

7.4K

Avg. volume:

5.5K

1-year change:

-99.7%

Market cap:

$65.4K

Revenue:

--

EPS (TTM):

-$9.05

Analysts' Opinion

Consensus Rating

No consensus rating exists at this time due to lack of analyst coverage.
Price Target Upside

No price target exists because of limited analyst coverage.
Price Target Downside

Similarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.

Fair Value

According to the consensus of 0 analysts, Vincerx Pharma, Inc. has 1599900% upside to fair value with a price target of $200.0000 per share.

VINC vs. S&P 500

Over the past 5 trading days, Vincerx Pharma, Inc. has underperformed the S&P 500 by -2.28% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

Vincerx Pharma, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

Vincerx Pharma, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Vincerx Pharma, Inc. reported revenues of --.

Earnings Growth

Vincerx Pharma, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Vincerx Pharma, Inc. reported earnings per share of -$1.40.

Enterprise value:

-4.5M

EV / Invested capital:

--

Price / LTM sales:

--

EV / EBIT:

--

EV / Revenue:

--

PEG ratio (5yr expected):

--

EV / Free cash flow:

0.20x

Price / Operating cash flow:

--

Enterprise value / EBITDA:

--

Gross Profit (TTM):

--

Return On Assets:

--

Net Income Margin (TTM):

--

Return On Equity:

--

Return On Invested Capital:

--

Operating Margin:

--

	Trailing 12 Months			Fiscal Quarters
Period Ending	2023-03-31	2024-03-31	2025-03-31	2024-03-31	2025-03-31
Income Statement
Revenue	--	--	--	--	--
Gross Profit	-$863K	-$1M	-$826K	-$264K	--
Operating Income	-$65M	-$34.7M	-$27.3M	-$7.5M	-$3.3M
EBITDA	-$64.2M	-$33.7M	-$26.5M	-$7.2M	-$3.3M
Diluted EPS	-$28.54	-$20.11	-$5.18	-$0.58	-$1.40

Period Ending	2021-03-31 FY-4	2022-03-31 FY-3	2023-03-31 FY-2	2024-03-31 FY-1	2025-03-31 Current FY
Balance Sheet
Current Assets	$54.4M	$98.1M	$44M	$7.7M	$4.7M
Total Assets	$66.2M	$103.9M	$47.4M	$11.1M	$4.7M
Current Liabilities	$29.2M	$11.5M	$10.7M	$10.6M	$2.6M
Total Liabilities	$32.4M	$14.7M	$13M	$11.7M	$2.6M
Total Equity	$33.7M	$89.2M	$34.5M	-$622K	$2.1M
Total Debt	$3.3M	$3.2M	$2.2M	$1M	--

	Trailing 12 Months			Fiscal Quarters
Period Ending	2023-03-31	2024-03-31	2025-03-31	2024-03-31	2025-03-31
Cash Flow Statement
Cash Flow Operations	-$57.7M	-$35.1M	-$22.8M	-$7.7M	-$4.5M
Cash From Investing	-$34.7M	$35.6M	$212K	--	--
Cash From Financing	$283K	$116K	$21.8M	$5K	$3.9M
Free Cash Flow	-$57.7M	-$35.1M	-$22.8M	-$7.7M	-$4.5M

VINC

Sector

Market Cap

$65.4K

--

Price % of 52-Week High

0.12%

--

Dividend Yield

0%

--

Shareholder Yield

--

1-Year Price Total Return

-99.7%

--

Beta (5-Year)

1.655

--

Dividend yield:

0%

Annualized payout:

$0.00

Payout ratio:

--

Growth streak:

0 years

Technicals

8-day SMA

Sell

Level $0.0125

200-day SMA

Sell

Level $0.1151

Bollinger Bands (100)

Sell

Level 0.0091 - 0.0491

Chaikin Money Flow

Sell

Level -6.9K

20-day SMA

Buy

Level $0.0123

Relative Strength Index (RSI14)

Sell

Level 45.1343

ADX Line

Buy

Level 19.9344

Williams %R

Sell

Level -16.6667

50-day SMA

Sell

Level $0.0160

MACD (12, 26)

Buy

Level 0.0028

25-day Aroon Oscillator

Buy

Level 8

On Balance Volume

Neutral

Level --

Financial Scores

Sell

Altman Z-Score (Annual)

Level (-44.5506)

Sell

CA Score (Annual)

Level (-11.1378)

--

Beneish M-Score (Annual)

Level (--)

Buy

Momentum Score

Level (1)

Sell

Ohlson Score

Level (19.1059)

--

Piotroski F Score (Annual)

Level (--)

--

Quality Ratio Score

Level (--)

--

Fundamental Score

Level (--)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. It focuses on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The firm pipeline is derived from a license agreement with Bayer and includes: a clinical-stage and follow-on small molecule drug program and preclinical stage bioconjugation/next-generation antibody-drug conjugate platform. The company was founded by Ahmed M. Hamdy, Raquel E. Izumi, Tom C. Thomas, Soo In Hwang and John C. Byrd on December 19, 2018 and is headquartered in Palo Alto, CA.

Stock Forecast FAQ

In the current month, VINC has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The VINC average analyst price target in the past 3 months is $200.0000.

Where Will Vincerx Pharma, Inc. Stock Be In 1 Year?

According to analysts, the consensus estimate is that Vincerx Pharma, Inc. share price will rise to $200.0000 per share over the next 12 months.
What Do Analysts Say About Vincerx Pharma, Inc.?

Analysts are divided on their view about Vincerx Pharma, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Vincerx Pharma, Inc. is a Sell and believe this share price will drop from its current level to $200.0000.
What Is Vincerx Pharma, Inc.'s Price Target?

The price target for Vincerx Pharma, Inc. over the next 1-year time period is forecast to be $200.0000 according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
Is VINC A Buy, Sell Or Hold?

According to Wall Street analysts, the consensus rating for Vincerx Pharma, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
How Can I Buy Shares Of VINC?

You can purchase shares of Vincerx Pharma, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Vincerx Pharma, Inc. shares.
What Is The Vincerx Pharma, Inc. Share Price Today?

Vincerx Pharma, Inc. was last trading at $0.0100 per share. This represents the most recent stock quote for Vincerx Pharma, Inc.. Yesterday, Vincerx Pharma, Inc. closed at $0.0125 per share.
How To Buy Vincerx Pharma, Inc. Stock Online?

In order to purchase Vincerx Pharma, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.